2025 third_quarter Filing
Q3Expenses
$230K
Method: A
Filed
October 20, 2025
Lobbying Activities
Health IssuesView all
Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; ORPHAN Cures Act and pharmacy benefit manager reform legislation (H.R. 1, One Big Beautiful Bill Act); Issues related to Most Favored Nation (MFN) pricing models
Contacted:Executive Office of the President (EOP), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
Lobbyists (1)
JOHN PAUL HALLIWELL